|Articles|June 15, 2004
Phakic IOL preserves endothelial cell count outcome measure
Study shows cell loss equal to natural aging, allowing IOL to be implanted in young patients
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Collarettes common but largely stable in moderate-to-severe dry eye patients
3
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
4
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
5













































.png)


